Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Technology review needed to help UK allergy diagnosis and care", says epidemiologist:

This article was originally published in Clinica

Executive Summary

There is an urgent need to review the technology involved in the diagnosis and monitoring of allergic conditions and their care, in light of the "dramatic increase" in prevalence of these across the western world, especially in the UK, which has one of the highest levels. So warned epidemiologist Aziz Sheikh, at his inaugural lecture as professor of primary care R&D, community health sciences, at Edinburgh University. Allergies affect some 40% of UK children and 30% of adults in the UK, and cost the NHS around £1bn ($1.8bn) per year, according to conservative estimates. He also cited the recent "scathing" House of Commons Health Select Committee's report on NHS provision of allergy services, in calling for an urgent review of these.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT055501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel